Cystic fibrosis transmembrane conductance regulator intracellular processing, trafficking, and opportunities for mutation-specific treatment

Chest

Volumn 139, Issue 6, 2011, Pages 1480-1490

  Rogan, Mark P ^a   Stoltz, David A ^b   Hornick, Douglas B ^b  

^a WATERFORD REGIONAL HOSPITAL   (Ireland)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHENYLBUTYRIC ACID; AGENTS AFFECTING PROTEIN METABOLISM; ARYLBUTYRIC ACID DERIVATIVE; ATALUREN; BUTYRIC ACID DERIVATIVE; CURCUMIN; GENTAMICIN; GLYCEROL; IVACAFTOR; PHENYLALANINE; PLACEBO; TOBRAMYCIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; VX 809; XANTHINE DERIVATIVE;

BRONCHIECTASIS; CHRONIC DISEASE; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE; DISEASE COURSE; DRUG MEGADOSE; GENE DELETION; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HIGH THROUGHPUT SCREENING; HUMAN; INTRACELLULAR TRANSPORT; MOLECULAR BIOLOGY; MUTATIONAL ANALYSIS; NEPHROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEFECT; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN STRUCTURE; PROTEIN TRANSPORT; RESPIRATORY FAILURE; REVIEW; STOP CODON; UNSPECIFIED SIDE EFFECT;

EID: 79958746554     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.10-2077     Document Type: Review

References (112)

1. Boat TF, Welsh MJ, Beaudet AL. Cystic fibrosis. In: Scriver CR, ed. The Metabolic Basis of Inherited Disease. New York, NY: McGraw-Hill; 1989:2649-2680.
2. Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am J Respir Crit Care Med. 1996;154(5):1229-1256. (Pubitemid 26391164)
3. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989;245(4922):1066-1073. (Pubitemid 19231814)
4. Quinton PM. Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis. Lancet. 2008;372(9636):415-417.
5. Riordan JR. CFTR function and prospects for therapy. Annu Rev Biochem. 2008;77:701-726.
6. Gelman MS, Kopito RR. Cystic fibrosis: premature degradation of mutant proteins as a molecular disease mechanism. Methods Mol Biol. 2003;232:27-37.
7. Lukacs GL, Mohamed A, Kartner N, Chang XB, Riordan JR, Grinstein S. Conformational maturation of CFTR but not its mutant counterpart (delta F508) occurs in the endoplasmic reticulum and requires ATP. EMBO J. 1994;13(24):6076-6086.
8. Ward CL, Kopito RR. Intracellular turnover of cystic fibrosis transmembrane conductance regulator. Inefficient processing and rapid degradation of wild-type and mutant proteins. J Biol Chem. 1994;269(41):25710- 25718.
9. Ward CL, Omura S, Kopito RR. Degradation of CFTR by the ubiquitin-proteasome pathway. Cell. 1995;83(1):121-127.
10. Cheung JC, Deber CM. Misfolding of the cystic fibrosis transmembrane conductance regulator and disease. Biochemistry. 2008;47(6):1465-1473. (Pubitemid 351231197)
11. Meacham GC, Patterson C, Zhang W, Younger JM, Cyr DM. The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation. Nat Cell Biol. 2001;3(1):100-105. (Pubitemid 32114840)
12. Younger JM, Ren HY, Chen L, et al. A foldable CFTRDeltaF508 biogenic intermediate accumulates upon inhibition of the Hsc70-CHIP E3 ubiquitin ligase. J Cell Biol. 2004;167(6):1075-1085. (Pubitemid 40066623)
13. Younger JM, Chen L, Ren HY, et al. Sequential qualitycontrol checkpoints triage misfolded cystic fibrosis transmembrane conductance regulator. Cell. 2006;126(3):571-582. (Pubitemid 44163603)
14. Turnbull EL, Rosser MF, Cyr DM. The role of the UPS in cystic fibrosis. BMC Biochem. 2007;8(suppl 1):S11.
15. Gelman MS, Kannegaard ES, Kopito RR. A principal role for the proteasome in endoplasmic reticulum-associated degradation of misfolded intracellular cystic fibrosis transmembrane conductance regulator. J Biol Chem. 2002;277(14):11709-11714. (Pubitemid 34952724)
16. Davies JE, Sarkar S, Rubinsztein DC. The ubiquitin proteasome system in Huntington's disease and the spinocerebellar ataxias. BMC Biochem. 2007;8(suppl 1):S2.
17. Harada K, Okiyoneda T, Hashimoto Y, et al. Calreticulin negatively regulates the cell surface expression of cystic fibrosis transmembrane conductance regulator. J Biol Chem. 2006;281(18):12841-12848. (Pubitemid 43855377)
18. Rosser MF, Grove DE, Chen L, Cyr DM. Assembly and misassembly of cystic fibrosis transmembrane conductance regulator: folding defects caused by deletion of F508 occur before and after the calnexin-dependent association of membrane spanning domain (MSD) 1 and MSD2. Mol Biol Cell. 2008;19(11):4570-4579.
19. Gnann A, Riordan JR, Wolf DH. Cystic fibrosis transmembrane conductance regulator degradation depends on the lectins Htm1p/EDEM and the Cdc48 protein complex in yeast. Mol Biol Cell. 2004;15(9):4125-4135. (Pubitemid 39122017)
20. Sun F, Zhang R, Gong X, Geng X, Drain PF, Frizzell RA. Derlin-1 promotes the efficient degradation of the cystic fibrosis transmembrane conductance regulator (CFTR) and CFTR folding mutants. J Biol Chem. 2006;281(48):36856- 36863. (Pubitemid 46042153)
21. Alberti S, Böhse K, Arndt V, Schmitz A, Höhfeld J. The cochaperone HspBP1 inhibits the CHIP ubiquitin ligase and stimulates the maturation of the cystic fibrosis transmembrane conductance regulator. Mol Biol Cell. 2004;15(9):4003-4010. (Pubitemid 39122006)
22. Wang X, Venable J, LaPointe P, et al. Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell. 2006;127(4):803-815. (Pubitemid 44716255)
23. Sun F, Mi Z, Condliffe SB, et al. Chaperone displacement from mutant cystic fibrosis transmembrane conductance regulator restores its function in human airway epithelia. FASEB J. 2008;22(9):3255-3263.
24. Glozman R, Okiyoneda T, Mulvihill CM, Rini JM, Barriere H, Lukacs GL. N-glycans are direct determinants of CFTR folding and stability in secretory and endocytic membrane traffic. J Cell Biol. 2009;184(6):847-862.
25. Wang X, Matteson J, An Y, et al. COPII-dependent export of cystic fibrosis transmembrane conductance regulator from the ER uses a di-acidic exit code. J Cell Biol. 2004;167(1):65-74. (Pubitemid 39363415)
26. Pagant S, Kung L, Dorrington M, Lee MC, Miller EA. Inhibiting endoplasmic reticulum (ER)-associated degradation of misfolded Yor1p does not permit ER export despite the presence of a diacidic sorting signal. Mol Biol Cell. 2007;18(9):3398-3413. (Pubitemid 47378680)
27. Koulov AV, Lapointe P, Lu B, et al. Biological and structural basis for Aha1 regulation of Hsp90 ATPase activity in maintaining proteostasis in the human disease cystic fibrosis. Mol Biol Cell. 2010;21(6):871-884.
28. Balch WE, Morimoto RI, Dillin A, Kelly JW. Adapting proteostasis for disease intervention. Science. 2008;319(5865):916-919. (Pubitemid 351263754)
29. Denning GM, Anderson MP, Amara JF, Marshall J, Smith AE, Welsh MJ. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature. 1992;358(6389):761-764.
30. Cheng SH, Gregory RJ, Marshall J, et al. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell. 1990;63(4):827-834. (Pubitemid 120035055)
31. Lukacs GL, Chang XB, Bear C, et al. The delta F508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. Determination of functional half-lives on transfected cells. J Biol Chem. 1993;268(29):21592-21598. (Pubitemid 23320650)
32. Lukacs GL, Segal G, Kartner N, Grinstein S, Zhang F. Constitutive internalization of cystic fibrosis transmembrane conductance regulator occurs via clathrin-dependent endocytosis and is regulated by protein phosphorylation. Biochem J. 1997;328(pt 2):353-361. (Pubitemid 27515573)
33. Sharma M, Pampinella F, Nemes C, et al. Misfolding diverts CFTR from recycling to degradation: quality control at early endosomes. J Cell Biol. 2004;164(6):923-933. (Pubitemid 38366903)
34. Okiyoneda T, Barrière H, Bagdany M, et al. Peripheral protein quality control removes unfolded CFTR from the plasma membrane. Science. 2010:329(5993):805-810
35. Chang XB, Mengos A, Hou YX, et al. Role of N-linked oligosaccharides in the biosynthetic processing of the cystic fibrosis membrane conductance regulator. J Cell Sci. 2008;121(pt 17):2814-2823.
36. Swiatecka-Urban A, Brown A, Moreau-Marquis S, et al. The short apical membrane half-life of rescued DeltaF508-cystic fibrosis transmembrane conductance regulator (CFTR) results from accelerated endocytosis of DeltaF508-CFTR in polarized human airway epithelial cells. J Biol Chem. 2005;280(44):36762-36772. (Pubitemid 41587756)
37. Winter MC, Welsh MJ. Stimulation of CFTR activity by its phosphorylated R domain. Nature. 1997;389(6648):294-296. (Pubitemid 27406644)
38. Csanády L, Seto-Young D, Chan KW, et al. Preferential phosphorylation of R-domain Serine 768 dampens activation of CFTR channels by PKA. J Gen Physiol. 2005;125(2):171-186. (Pubitemid 40224116)
39. Baker JM, Hudson RP, Kanelis V, et al. CFTR regulatory region interacts with NBD1 predominantly via multiple transient helices. Nat Struct Mol Biol. 2007;14(8):738-745. (Pubitemid 47220063)
40. Anderson MP, Berger HA, Rich DP, Gregory RJ, Smith AE, Welsh MJ. Nucleoside triphosphates are required to open the CFTR chloride channel. Cell. 1991;67(4):775-784. (Pubitemid 121001490)
41. Anderson MP, Welsh MJ. Regulation by ATP and ADP of CFTR chloride channels that contain mutant nucleotide-binding domains. Science. 1992;257(5077):1701-1704.
42. Lewis HA, Buchanan SG, Burley SK, et al. Structure of nucleotide-binding domain 1 of the cystic fibrosis transmembrane conductance regulator. EMBO J. 2004;23(2):282-293. (Pubitemid 38294493)
43. Vergani P, Basso C, Mense M, Nairn AC, Gadsby DC. Control of the CFTR channel's gates. Biochem Soc Trans. 2005;33(pt 5):1003-1007. (Pubitemid 41659100)
44. Aleksandrov AA, Aleksandrov LA, Riordan JR Jr. CFTR (ABCC7) is a hydrolyzable-ligand-gated channel. Pflugers Arch. 2007;453(5):693-702. (Pubitemid 46192540)
45. Bobadilla JL, Macek M Jr, Fine JP, Farrell PM. Cystic fibrosis: a worldwide analysis of CFTR mutations - correlation with incidence data and application to screening. Hum Mutat. 2002;19(6):575-606. (Pubitemid 34556480)
46. Worldwide survey of the delta F508 mutation - report from the Cystic Fibrosis Genetic Analysis Consortium. Am J Hum Genet. 1990;47(2):354-359.
47. Brown CR, Hong-Brown LQ, Biwersi J, Verkman AS, Welch WJ. Chemical chaperones correct the mutant phenotype of the delta F508 cystic fibrosis transmembrane conductance regulator protein. Cell Stress Chaperones. 1996;1(2):117-125. (Pubitemid 126670773)
48. Pedemonte N, Lukacs GL, Du K, et al. Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest. 2005;115(9):2564-2571. (Pubitemid 41266219)
49. Dorin JR, Farley R, Webb S, et al. A demonstration using mouse models that successful gene therapy for cystic fibrosis requires only partial gene correction. Gene Ther. 1996;3(9):797-801. (Pubitemid 26326685)
50. Johnson LG, Olsen JC, Sarkadi B, Moore KL, Swanstrom R, Boucher RC. Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat Genet. 1992;2(1):21-25.
51. Ramalho AS, Beck S, Meyer M, Penque D, Cutting GR, Amaral MD. Five percent of normal cystic fibrosis transmembrane conductance regulator mRNA ameliorates the severity of pulmonary disease in cystic fibrosis. Am J Respir Cell Mol Biol. 2002;27(5):619-627. (Pubitemid 35301816)
52. Farmen SL, Karp PH, Ng P, et al. Gene transfer of CFTR to airway epithelia: low levels of expression are sufficient to correct Cl- transport and overexpression can generate basolateral CFTR. Am J Physiol Lung Cell Mol Physiol. 2005;289(6):L1123-L1130. (Pubitemid 41681347)
53. Castellani C, Cuppens H, Macek M Jr, et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros. 2008;7(3):179-196.
54. Kerem B, Chiba-Falek O, Kerem E. Cystic fibrosis in Jews: frequency and mutation distribution. Genet Test. 1997;1(1):35-39. (Pubitemid 127526935)
55. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell. 1993;73(7):1251-1254. (Pubitemid 23201140)
56. Wilschanski M, Zielenski J, Markiewicz D, et al. Correlation of sweat chloride concentration with classes of the cystic fibrosis transmembrane conductance regulator gene mutations. J Pediatr. 1995;127(5):705-710.
57. Frischmeyer PA, Dietz HC. Nonsense-mediated mRNA decay in health and disease. Hum Mol Genet. 1999;8(10):1893-1900. (Pubitemid 29458667)
58. Van Goor F, Straley KS, Cao D, et al. Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol. 2006;290(6):L1117-L1130. (Pubitemid 43830856)
59. Hopfner KP, Karcher A, Shin DS, et al. Structural biology of Rad50 ATPase: ATP-driven conformational control in DNA double-strand break repair and the ABC-ATPase superfamily. Cell. 2000;101(7):789-800.
60. Sheppard DN, Rich DP, Ostedgaard LS, Gregory RJ, Smith AE, Welsh MJ. Mutations in CFTR associated with mild-diseaseform Cl- channels with altered pore properties. Nature. 1993;362(6416):160-164. (Pubitemid 23085256)
61. Kiesewetter S, Macek M Jr, Davis C, et al. A mutation in CFTR produces different phenotypes depending on chromosomal background. Nat Genet. 1993;5(3):274-278. (Pubitemid 23330392)
62. Kerem E. Pharmacological induction of CFTR function in patients with cystic fibrosis: mutation-specific therapy. Pediatr Pulmonol. 2005;40(3):183-196. (Pubitemid 41254489)
63. Kerem E, Corey M, Kerem BS, et al. The relation between genotype and phenotype in cystic fibrosis - analysis of the most common mutation (delta F508). N Engl J Med. 1990;323(22):1517-1522.
64. Davis PB. Cystic fibrosis since 1938. Am J Respir Crit Care Med. 2006;173(5):475-482.
65. Sermet-Gaudelus I, Vallée B, Urbin I, et al. Normal function of the cystic fibrosis conductance regulator protein can be associated with homozygous (Delta)F508 mutation. Pediatr Res. 2002;52(5):628-635. (Pubitemid 35286028)
66. Allan JL, Robbie M, Phelan PD, Danks DM. Familial occurrence of meconium ileus. Eur J Pediatr. 1981;135(3):291-292. (Pubitemid 11137455)
67. McKone EF, Goss CH, Aitken ML. CFTR genotype as a predictor of prognosis in cystic fibrosis. Chest. 2006;130(5):1441-1447. (Pubitemid 44786738)
68. Yankaskas JR, Marshall BC, Sufian B, Simon RH, Rodman D. Cystic fibrosis adult care: consensus conference report. Chest. 2004;125(1 suppl):1S-39S.
69. Flume PA, O'Sullivan BP, Robinson KA, et al;Cystic Fibrosis Foundation, Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007;176(10):957-969. (Pubitemid 350127838)
70. Flotte TR, Laube BL. Gene therapy in cystic fibrosis. Chest. 2001;120(3 suppl):124S-131S.
71. Carlile GW, Robert R, Zhang D, et al. Correctors of protein trafficking defects identified by a novel high-throughput screening assay. ChemBioChem. 2007;8(9):1012-1020. (Pubitemid 47189285)
72. Galietta LJ, Haggie PM, Verkman AS. Green fluorescent protein-based halide indicators with improved chloride and iodide affinities. FEBS Lett. 2001;499(3):220-224. (Pubitemid 32553868)
73. Galietta LV, Jayaraman S, Verkman AS. Cell-based assay for high-throughput quantitative screening of CFTR chloride transport agonists. Am J Physiol Cell Physiol. 2001;281(5):C1734-C1742.
74. Galietta LJ, Springsteel MF, Eda M, et al. Novel CFTR chloride channel activators identified by screening of combinatorial libraries based on flavone and benzoquinolizinium lead compounds. J Biol Chem. 2001;276(23):19723-19728.
75. Trzcinska-Daneluti A, Ly D, Huynh L, Jiang C, Fladd C, Rotin D. High-content functional screen to identify proteins that correct F508del-CFTR function. Mol Cell Proteomics; 2008:8(4):780-790.
76. Welch EM, Barton ER, Zhuo J, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature. 2007;447(7140):87-91. (Pubitemid 46685839)
77. Gorini L, Kataja E. Phenotypic repair by streptomycin of defective genotypes in E. coli. Proc Natl Acad Sci U S A. 1964;51:487-493.
78. Burke JF, Mogg AE. Suppression of a nonsense mutation in mammalian cells in vivo by the aminoglycoside antibiotics G-418 and paromomycin. Nucleic Acids Res. 1985;13(17):6265-6272.
79. Bedwell DM, Kaenjak A, Benos DJ, et al. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat Med. 1997;3(11):1280- 1284. (Pubitemid 27508832)
80. Du M, Jones JR, Lanier J, et al. Aminoglycoside suppression of a premature stop mutation in a Cftr-/- mouse carrying a human CFTR-G542X transgene. J Mol Med. 2002;80(9):595-604.
81. Wilschanski M, Yahav Y, Yaacov Y, et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med. 2003;349(15):1433-1441. (Pubitemid 37211058)
82. Clancy JP, Bebök Z, Ruiz F, et al. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med. 2001;163(7):1683-1692. (Pubitemid 32578776)
83. Clancy JP, Rowe SM, Bebok Z, et al. No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations. Am J Respir Cell Mol Biol. 2007;37(1):57-66. (Pubitemid 46999537)
84. Du M, Liu X, Welch EM, Hirawat S, Peltz SW, Bedwell DM. PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proc Natl Acad Sci U S A. 2008;105(6):2064-2069. (Pubitemid 351439465)
85. Hirawat S, Welch EM, Elfring GL, et al. Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multipledose administration to healthy male and female adult volunteers. J Clin Pharmacol. 2007;47(4):430-444. (Pubitemid 46465953)
86. Auld DS, Thorne N, Maguire WF, Inglese J. Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression. Proc Natl Acad Sci U S A. 2009;106(9):3585-3590.
87. Sermet-Gaudelus I, Boeck KD, Casimir GJ, et al. Ataluren (PTC124) induces CFTR protein expression and activity in children with nonsense mutation cystic fibrosis. Am J Respir Crit Care Med. 2010:182(10):1262-1272.
88. Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet. 2008;372(9640):719-727.
89. Wang Y, Loo TW, Bartlett MC, Clarke DM. Correctors promote maturation of cystic fibrosis transmembrane conductance regulator (CFTR)-processing mutants by binding to the protein. J Biol Chem. 2007;282(46):33247-33251. (Pubitemid 350159496)
90. Sato S, Ward CL, Krouse ME, Wine JJ, Kopito RR. Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J Biol Chem. 1996;271(2):635-638. (Pubitemid 26034907)
91. Nigam SK, Goldberg AL, Ho S, Rohde MF, Bush KT, Sherman MYu. A set of endoplasmic reticulum proteins possessing properties of molecular chaperones includes Ca(2+)-binding proteins and members of the thioredoxin superfamily. J Biol Chem. 1994;269(3):1744-1749.
92. Egan ME, Pearson M, Weiner SA, et al. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science. 2004;304(5670):600-602. (Pubitemid 38541921)
93. Dragomen A, Boosted J, Helter L, Romans GM. Curcumin does not stimulate cAMP-mediated chloride transport in cystic fibrosis airway epithelial cells. Biochem Biophys Res Commun. 2004;322(2):447-451.
94. Grubb BR, Gabriel SE, Mengos A, et al. SERCA pump inhibitors do not correct biosynthetic arrest of deltaF508 CFTR in cystic fibrosis. Am J Respir Cell Mol Biol. 2006;34(3):355-363. (Pubitemid 43320717)
95. Rubenstein RC, Egan ME, Zeitlin PL. In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. J Clin Invest. 1997;100(10):2457-2465. (Pubitemid 27514885)
96. Rubenstein RC, Zeitlin PL. A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. Am J Respir Crit Care Med. 1998;157(2):484-490. (Pubitemid 28090539)
97. Zeitlin PL, Diener-West M, Rubenstein RC, Boyle MP, Lee CK, Brass-Ernst L. Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. Mol Ther. 2002;6(1):119-126. (Pubitemid 36124279)
98. Choo-Kang LR, Zeitlin PL. Induction of HSP70 promotes DeltaF508 CFTR trafficking. Am J Physiol Lung Cell Mol Physiol. 2001;281(1):L58-L68.
99. Dormer RL, Harris CM, Clark Z, et al. Sildenafil (Viagra) corrects DeltaF508-CFTR location in nasal epithelial cells from patients with cystic fibrosis. Thorax. 2005;60(1):55-59. (Pubitemid 40101019)
100. Poschet JF, Timmins GS, Taylor-Cousar JL, et al. Pharmacological modulation of cGMP levels by phosphodiesterase 5 inhibitors as a therapeutic strategy for treatment of respiratory pathology in cystic fibrosis. Am J Physiol Lung Cell Mol Physiol. 2007;293(3):L712-L719. (Pubitemid 47358834)
101. Robert R, Carlile GW, Pavel C, et al. Structural analog of sildenafil identified as a novel corrector of the F508del-CFTR trafficking defect. Mol Pharmacol. 2008;73(2):478-489. (Pubitemid 351159218)
102. Loo TW, Bartlett MC, Clarke DM. Rescue of DeltaF508 and other misprocessed CFTR mutants by a novel quinazoline compound. Mol Pharm. 2005;2(5):407-413. (Pubitemid 41503681)
103. Wang Y, Loo TW, Bartlett MC, Clarke DM. Additive effect of multiple pharmacological chaperones on maturation of CFTR processing mutants. Biochem J. 2007;406(2):257-263. (Pubitemid 47310956)
104. Van Goor F, Hadida S, Grootenhuis PD, et al. VX-809, a CFTR corrector, increases the cell surface density of functional f508del-CFTR in pre-clinical models of cystic fibrosis. Pediatr Pulmonol. 2009;44(2):154-155.
105. Clancy JP, Rowe SM, Accurso FJ, Ballmann M, Boyle MP, DeBoeck C, Konstan MW, Spencer-Green G. A phase II, randomized, placebo-controlled, clinical trial of four doses of VX-809 in CF patients homozygous for the F508del CFTR mutation. Pediatr Pulmonol. 2010;45(3):228.
106. Al-Nakkash L, Hwang TC. Activation of wild-type and deltaF508-CFTR by phosphodiesterase inhibitors through cAMP-dependent and -independent mechanisms. Pflugers Arch. 1999;437(4):553-561. (Pubitemid 29110907)
107. Lim M, McKenzie K, Floyd AD, Kwon E, Zeitlin PL. Modulation of deltaF508 cystic fibrosis transmembrane regulator trafficking and function with 4-phenylbutyrate and flavonoids. Am J Respir Cell Mol Biol. 2004;31(3):351-357. (Pubitemid 39180306)
108. Pedemonte N, Sonawane ND, Taddei A, et al. Phenylglycine and sulfonamide correctors of defective delta F508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating. Mol Pharmacol. 2005;67(5):1797-1807. (Pubitemid 40594181)
109. Noel S, Faveau C, Norez C, Rogier C, Mettey Y, Becq F. Discovery of pyrrolo[2,3-b]pyrazines derivatives as submicromolar affinity activators of wild type, G551D, and F508del cystic fibrosis transmembrane conductance regulator chloride channels. J Pharmacol Exp Ther. 2006;319(1):349-359. (Pubitemid 44455142)
110. Van Goor F, Hadida S, Grootenhuis PD, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A. 2009;106(44):18825-18830.
111. Accurso FJ, Rowe SM, Clancy JP, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 2010;363(21):1991- 2003.
112. Jain KK. Challenges of drug discovery for personalized medicine. Curr Opin Mol Ther. 2006;8(6):487-492. (Pubitemid 44921803)